Following the rollout of COVID-19 testing mandates by the Center for Disease Control for cruise ship crew members and passengers, Radeas responded by empowering safe embarkations with an efficient, reliable solution. Radeas developed a system which provided CLIA certified mobile lab units to perform high throughput, fast turnaround PCR testing directly at the port. On-site COVID-19 testing simplified the travel process for passengers by providing safe, convenient, and accurate results.
The cruise industry recognized the need for transparency and accuracy as crew members and passengers returned to travel. Radeas’ development of mobile lab units made a significant impact on the revival of the cruise line industry, testing for over 200 departures. In all, Radeas tested and reported an estimated 500,000 samples for cruise passengers and staff during their effort. With the ability to deploy the mobile fleet directly to ports in less than 48 hours, and an average turnaround time for results under 30 minutes, Radeas utilized innovative technology, efficient service, and the highest standard of accuracy to enable safe sailing.
The cruise industry was especially affected by COVID-19 at the start of the pandemic. Many cruise lines suspended their operations entirely during the initial wave of the pandemic. Those that continued to provide their travel services have implemented additional protocols to ensure the safety of the passengers and crew members.
Due to the high demand for COVID-19 testing kits and the requirement for all passengers to be tested, Radeas has been able to fulfill the cruise industry's needs to allow for these businesses to function again. Not only is this benefiting the cruise industry, but it’s also providing people the ability to travel abroad and vacation on cruise ships again without having to worry about an outbreak on board. With these advances in testing and technologies, Radeas has been instrumental in getting families back together, and life back to normal during the COVID-19 pandemic.
About Radeas
Radeas was founded as a clinical toxicology lab in 2013, and has since evolved to provide clinical chemistry, toxicology, clinical labs, molecular diagnostics, PGx, SARS-CoV-2, COVID variant identification, and a range of other solutions. Radeas endeavors to provide efficient, effective testing results. The company’s website at radeas.com contains additional information.
Media Contact
Company Name: Radeas Labs
Contact Person: Casey Moul
Email: Send Email
Phone: 919-263-1150
Country: United States
Website: http://radeas.com/
